AI in Drug Development: Moving Beyond Early Use Cases
As new rules take hold, what does “good AI practice” look like in drug development?
False
Advertisement
Related Content
Interviews
Bioprocessing
Business & Trends
What Trump’s Latest Moves Mean for the Industry
May 27, 2025
6 min read
Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.
Regulation & Standards
Business & Trends
Regulators Target Ebola
December 1, 2014
0 min read
Will FDA fast review and voucher incentives make a difference?
Regulation & Standards
Business & Trends
Safety First - Sizing Up Biologics Side Effects
December 2, 2014
0 min read
Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated – especially when products share the same name.
Small Molecules
Regulation & Standards
Business & Trends
United Science Stands
December 2, 2014
0 min read
Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).